Amphastar Pharmaceuticals, Inc. (AMPH) income statement
AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3013% below fair value
$29.10−0.07 (-0.24%)
Close on Nov 17, 2026Market cap $1.24BP/E 17.1Yield –
Amphastar Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 47.7%
- Operating margin
- 15.7%
- Net margin
- 10.8%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 2.40
- Debt to equity
- –
- Debt to assets
- 35.1%
- Cash to current liabilities
- 85.0%
Valuation
- P/E ratio
- 17.1
- Price to sales
- 1.70
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?